Loading
A phase 2 trial of Ciltacabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel is a phase 2 interventional study registered as NCT07149857 by Janssen Research & Development, LLC, with 60 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-04-12. Interventions recorded: Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, CAR-T cell therapy.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/